1 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 USPTO Study on Restriction Reform and Update on TC1600 Restriction Practice Action Plan.

Slides:



Advertisements
Similar presentations
1 TC1600 Restriction Practice Action Plan and Unity of Invention Study Bruce Kisliuk Group Director, TC1600 United States Patent and Trademark Office.
Advertisements

GNSO Working Session on the Vertical Integration PDP 4 December 2010.
0 Progress Report on Work for Establishing Mechanisms for Feedback and Analysis on WOISAs /ISRs 9 February 2014 PCT/MIA Quality Subgroup Meeting.
Freedom of Information Act 2000 and the PCT Audit Procedure Background: The Act was passed in November The Act will be fully in force by January.
August 2006 OSEP Project Director's Conference 1 Preparing Teachers to Teach All Children: The Impact of the Work of the Center for Improving Teacher Quality.
Brian A. Harris-Kojetin, Ph.D. Statistical and Science Policy
Bicoastal Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting RCE Progress Update Daniel Sullivan Director, TC1600 September 17, 2014.
Enhanced First Action Interview (EFAI) Pilot Program Wendy Garber Tech Center Director, 2100 United States Patent & Trademark Office.
July 8, Enhanced Examination Timing Control Robert A. Clarke Deputy Director Office of Patent Legal Administration
PPAC Outreach Effort Andrew Faile Assistant Deputy Commissioner for Patents.
February 2012 Presentation to the Biotechnology/Chemical/Pharmaceutical Customer Partnership Introduction to the Cooperative Patent Classification (CPC)
John J. Calvert Administrator, Inventor Assistance Program John J. Calvert Administrator, Inventor Assistance Program Patents – Past, Present and Future.
© 3M All Rights Reserved. July 20, 2010 Response to USPTO Request for Public Comment on Enhanced Examination Timing Control Initiative.
Green Technology Petition Pilot Robert W. Bahr. 2 Green Tech: Discussion Points 1. Authority and Overview: resources / overview 2.Petition Requirement:
Patent Quality Assurance Program. 2 Office of Patent Quality Assurance (OPQA) Deputy Commissioner for Patent Operations Office of Patent Quality Assurance.
The Camp Audit “Keep your friends close and your auditor closer”
Canada OPICCIPO Office de la propriété intellectuelle du Canada Un organisme d’industrie Canada Canadian Intellectual Property Office An Agency of Industry.
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.
Problem solving in project management
1 United States Patent and Trademark Office Revised PCT International Search and Preliminary Examination Guidelines Biotech/ChemPharm Customer Partnership.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
J.A.Kemp & Co. London Munich Oxford. FICPI ABC MEETING 2007 EPC 2000 Alan M. Senior 30 May 2007.
UNECE and OSCE joint event, Almaty, May 2012
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571)
Funding Opportunities at the Institute of Education Sciences Elizabeth R. Albro, Ph.D. Associate Commissioner Teaching and Learning Division National Center.
Water Supply Planning Initiative State Water Commission November 22, 2004.
1 Biotechnology/Chemical/Pharmaceutical Customer Partnership June 1, 2010 Valencia Martin-Wallace – Director, Technology Center 2400.
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
Second expert group meeting on Draft fiche on delegated act on the European code of conduct on partnership (ECCP) Cohesion Policy
Pilot Concerning Public Submission of Peer Reviewed Prior Art Jack Harvey Director, TC 2100 United States Patent and Trademark Office
Bankruptcy Law Reform Claire Orr Executive Director of Policy & Compliance.
Project Life Cycle – Project Initiation © Ed Green Penn State University All Rights Reserved.
Biotech Customer Partnership August 3, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571)
GOVERNOR’S EARLY CHILDHOOD ADVISORY COUNCIL (ECAC) September 9, 2014.
Claims and Continuations Final Rule Overview Briefing for Examiners 1.
1 Commonwealth Project Management Division Bob Haugh Project Management Division November 15, 2010 Revision of.
Lawrence T. Welch April, 2003 Company Confidential Copyright © 2003 Eli Lilly and Company FICPI/AIPLA Colloquium Reform of the Patent Cooperation Treaty.
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
The University of Kentucky Program Review Process for Administrative Units April 18 & 20, 2006 JoLynn Noe, Assistant Director Office of Assessment
Pilot Concerning Public Submission of Peer Reviewed Prior Art Jack Harvey Director, TC 2100.
Consideration Towards Development of Intellectual Property System Dr. Li Yuguang Deputy Commissioner the State Intellectual Property Office of P. R. China.
1 Restriction Petition Survey; A Few Helpful Hints Julie Burke TC1600 Special Program Examiner
Chris Fildes FILDES & OUTLAND, P.C. IP Practice in Japan Committee Pre-Meeting AIPLA Annual Meeting, October 20, 2015 USPTO PILOT PROGRAMS 1 © AIPLA 2015.
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
JPO’s Initiatives for World‘s Best Examination Quality January, 2015 JAPAN PATENT OFFICE.
June 13, Biotechnology/Chemical/Pharmaceutical Customer Partnership USPTO Study on Restriction Reform and TC1600 Restriction Practice Action Plan.
Bruce Kisliuk Group Director, Technology Center 1600.
FY 2010 and FY 2011 USPTO Financial Report Trademark Public Advisory Committee Meeting February 25, 2010.
1 Drivers for Implementation of TC 1600 Restriction Practice Action Plan: Public comments from bar groups, and customer partnerships starting before the.
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Technical Resources Assistance Center.
Accelerated Patent Examination: Green Technology A Summary of Global Initiatives, with specific discussion of the US Speaker: Matt Prater Preparation help.
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
IP Community Outreach (Suite of Patent Products) Andrew Faile Director, TC 2600 United States Patent and Trademark Office
DG Enterprise and Industry European Commission Standardisation Aspects of ICT and e-Business Antonio Conte Unit D4 - ICT for Competitiveness and Innovation.
Yuichi Watanabe Osha Liang LLP January 26, 2016 Practice Tips: Prosecution of Japan-origin US applications 1 © AIPLA 2015.
Evaluating a Task-based English Course: A Proposed Model
CBP Biennial Strategy Review System
FDA’s IDE Decisions and Communications
IDN Variant TLDs Program Update
CBP Biennial Strategy Review System ~Meetings Detail~ DRAFT August 29, /6/2018 DRAFT.
CBP Biennial Strategy Review System
Equitable Services Sections 1117 and 8501 of the Elementary and Secondary Education Act (ESEA), as amended by the Every Student Succeeds Act (ESSA),
Unity of invention – outcome of the IP5 work MEETING OF INTERNATIONAL AUTHORITIES – QUALITY SUBGROUP Camille Bogliolo (PCT Affairs) and Luigi Petrucci.
I. Review of TC1600 Restriction Practice Action Plan
Boston Patent Law Association Annual Meeting
Presentation transcript:

1 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 USPTO Study on Restriction Reform and Update on TC1600 Restriction Practice Action Plan Jasemine C. Chambers, Ph.D., J.D. Director, Technology Center 1600 U.S. Patent &Trademark Office (571) ;

2 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 USPTO Study on Restriction Reform

3 Background  Study possible reforms to restriction standards applicable to all technologies  Part of 21 st Century Strategic Plan

4 USPTO Study on Restriction Reform Background (continued)  Strategic Plan  Initiate a study of the changes needed to implement a Patent Cooperation Treaty (PCT) style Unity of Invention standard in the United States.  Public Comment Notice published May 2003  No consensus to go to a PCT-style Unity standard.  Suggestions for other options made.  Revision of Study posted November 2003  Summary of public comments.  Study expanded to include four restriction reform options.

5 USPTO Study on Restriction Reform  Four Options  Option I: Current 35 U.S.C. §121 “independent or distinct” standard and option to request and pay for examination of up to 2 additional independent or distinct inventions for an additional fee.  Option II: Current PCT “unity of invention” standard (modified to require that any purported special technical/common feature comply with 35 U.S.C. §112, 1 st paragraph), and option to request and pay for examination of up to 2 additional inventions that lack unity of invention for an additional fee.

6 USPTO Study on Restriction Reform  Four Options (Continued)  Option III: New three-tiered structure based on the related-ness of the inventions (substantially similar, related, and unrelated), and fees would associated with the related-ness.  Option IV: Re-interpreted “independent and distinct” standard.

7 USPTO Study on Restriction Reform  Steps of the Study  Develop details of the standards for each the four options.  Sample a representative number of restrictions (about 500), review and apply standard under each of the four options.  Compile the data from the reviews and validate data.  Perform the business analysis and impacts based on review data and process changes.  Draft the “Green Paper.”

8 USPTO Study on Restriction Reform  Steps of the Study (Continued)  June 6, 2005 – Publish Green Paper  “Notice of Availability of and Request for Comments on Green Paper Concerning Restriction Practice,” 70 FR 107 (June 6, 2005)  Green Paper available at  Comment period ends August 5,  Next Steps – Assess the public comments prior to considering the desirability of drafting any proposed legislative changes in a final “White Paper.”

9 USPTO Study on Restriction Reform Green Paper Conclusions/Recommendations:  Options 3 and 4 –  Development of standards highlights the difficulty in formulation of any new standard.  Not considered viable for implementation.  Options 1 and 2 – Somewhat more promising in terms of the standards being more workable to implement, the business analysis indicates these would not achieve a desired balance due to workload and pendency impacts.  The process of improving the quality and predictability of restriction requirements must be a collaborative effort.  This paper and the TC1600 Restriction Action Plan represent only the first step in an ongoing endeavor to discover feasible solutions.

10 USPTO Study on Restriction Reform Green Paper Conclusions/Recommendation (Continued):  The Office requests comments from the public on:  The desirability of conducting further study on Options 1 and 2.  Whether the perceived desirability justifies the costs to the Office of continuing the study  The impact on the system as a whole.  Appropriate legislation would need to be enacted in the event a decision to implement Option 1 or 2 is made.  Implementation of Option 1 would not be viable without a revision to the fees for search/examination, issue and maintenance.  Implementation of Option 2 would require revision to 35 U.S.C. § 121 in addition to the same fee revisions required to implement Option 1.

11 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 Update on TC1600 Restriction Practice Action Plan

12 TC1600 Restriction Practice Action Plan Background:  Announced October 2003  Improve quality and consistency of restrictions in TC1600

13 TC1600 Restriction Practice Action Plan The action plan includes 5 initiatives: 1.Emphasis On Rejoinder Practice Policy memos to examiners 2.Examiner Training On Restriction Practice Phase I training completed and training materials posted Aug Publish Examples Of Claim Sets Part of training materials, more to come in subsequent Phases 4.Enhanced Review Of Restriction Requirements Rolling review of Art Units 5.Continuous Assessment Second Pair of Eyes reviews, petition decisions

14 TC1600 Restriction Practice Action Plan  Phase I Training (August 2004)  Focused on restriction fundamentals  Basic criteria for restrictions  Linking claims  Rejoinder opportunities  Included example claims and restriction requirements  Next Steps  Developing further training on relationships of inventions specific to biotechnology

15 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 Thank You Jasemine C. Chambers, Ph.D., J.D. Director, Technology Center 1600 U.S. Patent &Trademark Office (571) ;